Mocravimod as a repurposing drug against clinical isolates of Staphylococcus aureus by targeting cell membrane
Evaluating the antibacterial and antibiofilm activity of mocravimod hydrochloride (KRP-203), an FDA-approved S1P receptor modulator, against clinical S. aureus isolates revealed its potential as a repurposed antibacterial agent, but further studies are required to fully elucidate its molecular targets, optimize antibac...